Our results are in accordance with previous studies reporting the anti-inflammatory actions of pioglitazone in coronary arteriosclerosis by reducing the expression of CCL2 receptor (CCR2) [53] as well as in traumatic brain injury by modulating the PPARγ/NF-κB/IL-6 pathway [54]. This evidence concerns the gene PPARG and coronary artery disorder.